Cipla announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the United States Food and Drug Administration (US FDA).
Cipla's Difluprednate Ophthalmic Emulsion 0.05% is AB-rated generic therapeutic equivalent version of Novartis Pharmaceutical Corporation's Durezol.
It is used for the following:
Treatment of inflammation and pain associated with ocular surgery.
Treatment of endogenous anterior uveitis.
According to IQVIA (IMS Health), Durezol had US sales of approximately $106mn for the 12-month period ending June 2021.
The product will be available for shipping soon.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
